Literature DB >> 25548957

Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients.

Hazuki Watanabe1, Naoki Atsuta, Ryoichi Nakamura, Akihiro Hirakawa, Hirohisa Watanabe, Mizuki Ito, Jo Senda, Masahisa Katsuno, Yuishin Izumi, Mitsuya Morita, Hiroyuki Tomiyama, Akira Taniguchi, Ikuko Aiba, Koji Abe, Kouichi Mizoguchi, Masaya Oda, Osamu Kano, Koichi Okamoto, Satoshi Kuwabara, Kazuko Hasegawa, Takashi Imai, Masashi Aoki, Shoji Tsuji, Imaharu Nakano, Ryuji Kaji, Gen Sobue.   

Abstract

Our objective was to elucidate the clinical factors affecting functional decline and survival in Japanese amyotrophic lateral sclerosis (ALS) patients. We constructed a multicenter prospective ALS cohort that included 451 sporadic ALS patients in the analysis. We longitudinally utilized the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) as the functional scale, and determined the timing of introduction of a tracheostomy for positive-pressure ventilation and death. A joint modelling approach was employed to identify prognostic factors for functional decline and survival. Age at onset was a common prognostic factor for both functional decline and survival (p < 0.001, p < 0.001, respectively). Female gender (p = 0.019) and initial symptoms, including upper limb weakness (p = 0.010), lower limb weakness (p = 0.008) or bulbar symptoms (p = 0.005), were related to early functional decline, whereas neck weakness as an initial symptom (p = 0.018), non-use of riluzole (p = 0.030) and proximal dominant muscle weakness in the upper extremities (p = 0.01) were related to a shorter survival time. A decline in the ALSFRS-R score was correlated with a shortened survival time (p < 0.001). In conclusion, the factors affecting functional decline and survival in ALS were common in part but different to some extent. This difference has not been previously well recognized but is informative in clinical practice and for conducting trials.

Entities:  

Keywords:  ALS; ALSFRS-R; functional decline; survival

Mesh:

Year:  2014        PMID: 25548957     DOI: 10.3109/21678421.2014.990036

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  23 in total

1.  Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.

Authors:  Jinsy A Andrews; Lisa Meng; Sarah F Kulke; Stacy A Rudnicki; Andrew A Wolff; Michael E Bozik; Fady I Malik; Jeremy M Shefner
Journal:  JAMA Neurol       Date:  2018-01-01       Impact factor: 18.302

2.  Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

3. 

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

4.  Age of onset differentially influences the progression of regional dysfunction in sporadic amyotrophic lateral sclerosis.

Authors:  Daichi Yokoi; Naoki Atsuta; Hazuki Watanabe; Ryoichi Nakamura; Akihiro Hirakawa; Mizuki Ito; Hirohisa Watanabe; Masahisa Katsuno; Yuishin Izumi; Mitsuya Morita; Akira Taniguchi; Masaya Oda; Koji Abe; Kouichi Mizoguchi; Osamu Kano; Satoshi Kuwabara; Ryuji Kaji; Gen Sobue
Journal:  J Neurol       Date:  2016-04-15       Impact factor: 4.849

5.  Serum C-Reactive Protein as a Prognostic Biomarker in Amyotrophic Lateral Sclerosis.

Authors:  Christian Lunetta; Andrea Lizio; Eleonora Maestri; Valeria Ada Sansone; Gabriele Mora; Robert G Miller; Stanley H Appel; Adriano Chiò
Journal:  JAMA Neurol       Date:  2017-06-01       Impact factor: 18.302

6.  Heterogeneity in ALSFRS-R decline and survival: a population-based study in Italy.

Authors:  Jessica Mandrioli; Sara Biguzzi; Carlo Guidi; Elisabetta Sette; Emilio Terlizzi; Alessandro Ravasio; Mario Casmiro; Fabrizio Salvi; Rocco Liguori; Romana Rizzi; Vladimiro Pietrini; Annamaria Borghi; Rita Rinaldi; Nicola Fini; Elisabetta Chierici; Mario Santangelo; Enrico Granieri; Vittoria Mussuto; Silvia De Pasqua; Eleni Georgoulopoulou; Antonio Fasano; Salvatore Ferro; Roberto D'Alessandro
Journal:  Neurol Sci       Date:  2015-07-24       Impact factor: 3.307

7.  The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset.

Authors:  Malcolm Proudfoot; Ashley Jones; Kevin Talbot; Ammar Al-Chalabi; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2016-02-11       Impact factor: 4.092

8.  Milano-Torino Staging and Long-Term Survival in Chinese Patients with Amyotrophic Lateral Sclerosis.

Authors:  Ruojie He; Minying Zheng; Ling Lian; Xiaoli Yao
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

Review 9.  Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact.

Authors:  Fabiola De Marchi; Ivana Munitic; Amedeo Amedei; James D Berry; Eva L Feldman; Eleonora Aronica; Giovanni Nardo; Donatienne Van Weehaeghe; Elena Niccolai; Nikolina Prtenjaca; Stacey A Sakowski; Caterina Bendotti; Letizia Mazzini
Journal:  Neurosci Biobehav Rev       Date:  2021-06-19       Impact factor: 9.052

10.  Antecedent Disease and Amyotrophic Lateral Sclerosis: What Is Protecting Whom?

Authors:  Sabrina K Hollinger; Ike S Okosun; Cassie S Mitchell
Journal:  Front Neurol       Date:  2016-03-29       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.